Valneva Scotland announces year-long support for local cancer charity Team Jak
The company’s workforce will volunteer and fundraise for Team Jak throughout the year
Read More
Tag: Valneva
Valneva reveals chikungunya vaccine data
VLA1553 had a high seroresponse rate among participants 28 days after receiving a single administration
Read More
Vital update for Valneva’s COVID-19 vaccine
European Medicines Agency has issued a positive opinion for the use of VLA2001 among certain adults
Read More
Important milestone for Valneva’s chikungunya vaccine
VLA1553 is a single-dose, live-attenuated vaccine candidate targeting the highly dangerous chikungunya virus
Read More
Enrolment concluded for Valneva’s chikungunya vaccine
Phase 3 trial of single-shot chikungunya vaccine candidate unfolds among an adolescent cohort
Read More
Valneva delivers additional data for COVID-19 booster vaccine
Company has reported booster details from a study of its inactivated COVID-19 candidate
Read More
Valneva shares positive chikungunya vaccine results
99% of participants retained very high neutralising antibody levels 12 months after treatment
Read More
Valneva and Pfizer report Lyme disease antibody data
Children and adults have been treated using the Lyme disease antibody candidate VLA15
Read More
Valneva and VBI announce partnership for hepatitis B vaccine
Collaboration involves the marketing and distribution of PreHevbri across Europe
Read More
CHMP provides initial assessment of Valneva’s COVID-19 vaccine
Valneva expects to receive a positive CHMP recommendation for the conditional approval of its VLA2001 vaccine
Read More
UK terminates Valneva COVID-19 vaccine supply agreement
Gov has alleged that the company breached its obligations under the agreement
Read More
Valneva starts MHRA regulatory process for COVID-19 vaccine
VLA2001 is an inactivated, adjuvanted vaccine candidate
Read More
- Lario Therapeutics awarded $2.4m to advance calcium channel platform
- Mikrobiomik secures approval for gut‑microbiota therapy for C difficile infection
- Exdensur approved in EU for severe asthma and CRSwNP
- Axol Bioscience acquires Newcells Biotech ophthalmology unit
- Nuclera and leadXpro partner to accelerate structure‑based drug design
